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Dysregulation of microRNAs (miRNAs) has been implicated in almost every known survival mechanisms utilized by cancer cells.
One of such mechanisms, anoikis resistance, plays a pivotal role in enabling metastasis by allowing cancer cells to circumvent cell
death induced by lack of attachment. Understanding how miRNAs regulate the various anoikis pathways has become the research
question of increasing number of studies published in the past years. Through these studies, a growing list of miRNAs has been
identified to be important players in promoting either anoikis or resistance to anoikis. In this review, we will be focusing on these
miRNAs and how the findings from those studies can contribute to novel therapeutic strategies against cancer progression. We will
be examining miRNAs that have been found to promote anoikis sensitivity in numerous cancer types followed by miRNAs that
inhibit anoikis. In addition, we will also be taking a look at major signaling pathways involved in the action of the each of these
miRNAs to gain a better understanding on how miRNAs regulate anoikis.
1. Anoikis and Cancer
Attachment of a cell to the extracellular matrix (ECM) is
vital for the proliferation and survival functions to be carried
out efficiently. If a cell gets detached, apoptosis may be
induced. Cell death triggered by lack of attachment to the
ECM is defined as anoikis. This regulatory mechanism is
especially important for epithelial cells that undergo a robust
rate of renewal [1]. Apart from ensuring that cells are only
viable with the appropriate contact with ECM, anoikis is also
involved in limiting the progression of cancer. Since anoikis
was first characterized by Frisch and Francis 11 years ago [2],
increasing number of studies have uncovered the relationship
between anoikis inhibition and cancer.
Although complex regulatory systems have been iden-
tified to be involved in anoikis mechanisms [3–5], anoikis
mediated cell death can be grouped into two general path-
ways: intrinsic and extrinsic [6]. The intrinsic pathway
involves caspase enzymes that are activated as a result of per-
meabilization of outermitochondrialmembrane by proapop-
totic proteins, such as the members of B-cell lymphoma 2
(Bcl-2) family [7]. On the other hand, extrinsic pathway
involves death receptors, such as the tumor necrosis factor
(TNF) superfamily receptors, and the eventual activation
of caspase-8. Both pathways are not biologically distinct,
however, as it is known that the intrinsic pathway can also
be induced by caspase-8, when it is activated by extrinsic
pathway [8, 9].
The role of initiating anoikis comes down to proteins that
mediate cellular interaction with the ECM and neighboring
cells, such as integrins andE-cadherin. Integrins are receptors
made up of two components, 𝛼 and 𝛽 subunits. In its ligated
conformation, integrins can activate signaling pathways that
promote survival such as the PI3K/Akt pathway [10] and
promote apoptosis in its unligated conformation [9]. The
apoptotic response by integrins have been documented and
shown to be mediated through recruitment of caspase-8 [11,
12]. Meanwhile, E-cadherin is a transmembrane protein, with
the cytoplasmic domain being bound to 𝛽-catenin, which
then binds to 𝛼-catenin. As 𝛼-catenin can bind to the actin
filaments, the complex as a whole plays an important role
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of connecting E-cadherin to the cytoskeleton, allowing it to
regulate adhesion between cells [13, 14]. E-cadherin has also
been shown to regulate anoikis through the PI3K/Akt and
RAF/ERK pathways [15, 16]. For example, E-cadherin was
found to be necessary for anoikis evasion in the absence
of ECM in hepatocyte spheroids [17]. Furthermore, the
loss of E-cadherin and gain of N-cadherin expression, the
hallmark of epithelial-to-mesenchymal transition (EMT), has
been repeatedly shown to promote inhibition of anoikis and
subsequently enable metastasis [18, 19].
Acquisition of anoikis resistance is crucial in the pro-
gression of cancer cells to become metastatic. For example,
anoikis resistance has been shown to be necessary for sphere
formation. Sphere formation is a well-known capability of
stem cells, although cancer cells have also been shown to
undergo dedifferentiation to initiate sphere formation [20,
21]. With respect to tumorigenesis, sphere formation is an
important characteristic of an aggressive cancer as it enables
cancer cells to metastasize and initiate secondary tumor
formation [22].
2. Anoikis and Cancer Associated MicroRNAs
MicroRNAs or miRNAs are short strands of RNAmolecules,
usually ranging between 17 and 27 nucleotides in size.
These miRNA molecules play an integral role in regulating
messenger RNAs (mRNA) after transcription.This regulatory
mechanism involves the binding ofmiRNA to a targetmRNA
with complementary sequence, leading to the degradation of
the mRNA [23]. By directly interacting with mRNA, miRNA
is capable of silencing the expression of a target gene. The
complexities of miRNA lie in the fact that a single miRNA
can regulate multiple genes [24] and multiple miRNAs can
regulate the same gene [25]. MiRNAs are well known to
be dysregulated in various cancer types. This has led to
an increasing amount of publications examining the role
that these small sequences of nucleotide play in promoting
and inhibiting cancer. As such, it comes as no surprise that
numerous miRNAs have been found to play a pivotal role
in disrupting various pathways regulating anoikis, to either
confer anoikis resistance or anoikis sensitivity.
In this review, such miRNAs (Figure 1) and how the
findings from these studies can be utilized for therapeutic
purposes are examined. We will first look at miRNAs that
have been found to promote anoikis sensitivity in various
cancer cell lines and the mechanisms through which it takes
place. MiRNAs that play a role in inhibiting anoikis have also
been identified and are reviewed as well. In addition, key
pathways involved in the regulation of anoikis bymiRNAs are
highlighted to elucidate the underlying mechanisms.
3. MiRNAs Promoting Anoikis Sensitivity
The expression of miRNAs promoting anoikis is often down-
regulated in various cancer types, especially in variants that
show anchorage independent growth. By performing various
in vitro studies, the role played by suchmiRNAs in promoting
anoikis has been demonstrated (Table 1(a)).
3.1. miR-204. In a study conducted by Zhang et al. (2013),
downregulation of miR-204 was found to promote gastric
cancer cell invasion by disrupting SIRT1-LKB1 pathway [26].
Liver kinase B1 (LKB1) is a tumor suppressor known to
regulate the AMP-activated protein kinase (AMPK) family
consisting of 13 kinases, which ultimately regulates a wide
array of cellular processes such as cell growth, cell polarity,
and energymetabolism [27].However, a study done byCheng
et al. (2009) reported that LKB1 is also coupled to the p53-
dependent anoikis [28]. Previous studies by the authors have
shown sirtuin 1 (SIRT1) to be correlated to an aggressive
metastatic phenotype in gastric cardiac carcinoma [26].
SIRT1, a class III histone deacetylase, exerts inhibitory effects
against LKB1 by targeting it for degradation, subsequently
promoting anoikis resistance and EMT. Luciferase reporter
assay was able to confirm SIRT1 to be the direct target of miR-
204 and overexpression ofmiR-204 elevated LKB1 expression
and increased anoikis sensitivity in gastric cancer cells.
Another recent study done by Wang and colleagues
reported findings that miR-204 was similarly downregulated
in human posterior capsule opacification (POC) tissue [29].
Although not tumorigenic, POC is the result of normal at-
tached lens epithelial cells (LEC) undergoing EMT due to the
aggravation caused by cataract surgery. Interestingly, in this
study Smad4 was found to be the target of miR-204, which
is a part of the TGF-𝛽/Smad signaling pathway, suggesting
a complex regulatory role played by miR-204 in promoting
anoikis and repressing EMT in epithelial cells.
3.2. miR-26a. MiR-26a has already been well established
as a tumor suppressor miRNA in hepatocellular carcinoma
(HCC), with roles of inhibiting tumor growth, metastasis
[30], and angiogenesis [31]. Another recent study by Zhang
et al. (2015) demonstrated how miR-26a specifically pro-
moted anoikis in HCC. In their study, they found that
miR-26a was downregulated, corresponding to an increased
expression of integrin alpha-5 (ITGA5) in HCC [32]. ITGA5
forms a heterodimer complex with integrin beta-1 (ITGB1)
to form the 𝛼5𝛽1 integrin, which is capable of activating the
focal adhesion kinase (FAK) [33] and suppressing anoikis.
Overexpression studies in both in vivo and in vitro proved
miR-26a increases anoikis sensitivity inHCC, consistent with
its function of targeting ITGA5. In addition, overexpression
of miR-26a also revealed a reduced Akt phosphorylation in
tandem with reduced expression of ITGA5, suggesting that
the PI3K/Akt pathway is also negatively regulated by this
miR-26a. As this miRNAnegatively regulates multiple targets
that are involved in inhibiting anoikis, miR-26a makes an
ideal candidate for therapeutic approach for liver cancer.
3.3. miR-31. Valastyan et al. (2009) demonstrated that over-
expression of miR-31 in breast cancer cell lines returned
sensitivity to anoikis mediated cell death, as much as 60%
as was shown in MDA-MB-231 cell line [34]. Computational
analysis revealed a list of miR-31 targets, most of them being
genes regulating motility-related processes. From this list of
genes, luciferase reporter assay and siRNAmediated silencing
revealed RhoA and ITGA5 to be the two most prominent
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Figure 1: Schematic figure illustrating how miRNAs both positively and negatively regulate anoikis by targeting and manipulating key
components of various signaling pathways.
anoikis related genes targeted by miR-31. RhoA, a small G
protein belonging to the Rho family, is regulated by the
PI3K/Akt pathway. Inhibition of RhoA inmelanoma cells has
shown to increase rate of anoikis by inactivating FAK and
reducing ITGA5 integrin expression in melanoma cells [35].
In addition to be regulated by RhoA, ITGA5 was also shown
to be negatively regulated by miR-31, similar to miR-26a [32],
as a mechanism to promote anoikis in a variety of breast
cancer cell lines by Valastyan and colleagues.
Interestingly, despite being able to suppress metastasis
in vitro, in vivo studies uncovered that ectopic expression
of miR-31 resulted in increased growth of primary tumor
in mice, highlighting the complexities of miRNA regulation.
Similar characteristics have also been observed with other
miRNAs playing multiple roles, each utilizing independent
pathways [36, 37].
3.4. miR-451. Based on a previous study that confirmedmiR-
451 role in promoting anoikis [38], Tian and colleagues
were able to identify the target of miR-451 to be CAB39,
which is part of the LKB1-STRAD-MO25 complex [39].
This complex which is bound to LKB1 ensures that LKB1 is
activated and localized in the cytoplasm [40], which in turn
activates the P13K/Akt pathway.The relationship between the
LKB1/AMPK and the PI3K/Akt pathways has already been
established as well [41], where AMPK was found to activate
Akt.Western blot on human glioma transfectedwithmiR-451
mimics showed a reduced expression of multiple signaling
factors upstream of Akt, such as LKB1, AMPK, and PI3K.
These results suggest that miR-451 promotes sensitivity to
anoikis in human glioma by inhibiting the expression of
CAB39 and disrupting the P13K/Akt pathway.
In addition to glioma cells, miR-451 has also shown to
promote anoikis sensitivity when overexpressed in nonsmall
cell lung cancer (NSCLC) [42]. However, in this study, RAB14
was identified as a novel target of miR-451. Belonging to
the Ras oncogene family, RAB14 inhibition through miR-451
overexpression resulted in a decreased phosphorylation of
Akt, consequently promoting anoikis in NSCLC.
3.5. miR-200b. miR-200b belongs to the miR-200 family,
which is well studied and established for their role in
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Table 1: MiRNAs known to play roles in (a) promoting anoikis and (b) inhibiting anoikis.
(a)
MiRNA Cancer type Target Signalling pathway Reference
miR-204 Gastric SIRT1 SIRT1-LKB1, PI3K/AKT [26, 29]
miR-26a Liver ITGA5 PI3K/AKT [30–32]
miR-31 Breast RhoA, ITGA5 PI3K/AKT [34]
miR-451 GliomaNonsmall cell lung cancer
CAB39
Rab14 PI3K/AKT
[38, 39]
[42]
miR-200b Breast Pin1 PI3K/AKT [43]
miR-200c Breast TrkB PI3K/AKT [44–46]
miR-424-5p Liver CAT/CTNNBIP1 Wnt [47]
miR-494 Pancreatic FOXM1 Wnt [48]
(b)
MiRNA Cancer type Target Signalling pathway Reference
miR-125b — p53 MAP/ERK [49]
miR-181a Breast Bim — [50]
miR-145 Esophageal — — [51]
miR-421 Pancreatic Smad4 TGF-𝛽/SMAD [52]
miR-146a Leukemia Smad4 TGF-𝛽/SMAD [53–56]
miR-483-3p Pancreatic Smad4 TGF-𝛽/SMAD [57, 58]
miR-199a Gastric Smad4 TGF-𝛽/SMAD [59]
regulating E-cadherin. One of the miR-200 family members,
miR-200b, was found to promote anoikis by negatively regu-
lating Pin1 expression, which was confirmed using luciferase
reporter assay [43]. Pin1 is crucial for the stability of activated
ERK and Akt, as it binds and regulates the phosphorylated
conformation of those signaling proteins [60, 61]. Conse-
quently, elevated level of Pin1 is one of the mechanisms used
by cancer cells to avoid anoikis through the activation of the
ERK/Akt pathway. In the study by Zhang and colleagues,
anoikis promoting effect of miR-200b was evident when
overexpression of miR-200b resulted in increased sensitivity
to anoikis in MDA-MB-231 breast cancer cell line, while
coexpressing miR-200b with Pin1 negated that effect [43].
In addition to regulation of anoikis by miR-200b, the
authors also investigated how miR-200b itself is regulated.
Analysis on miR-200b promoter showed that it contained
binding sites for polyomavirus enhancer activator 3 (PEA3)
and ELK-1, both members of a larger E-twenty-six (Ets)
family that have been previously implicated as upstream
regulators ofmiRNAs [62, 63].The authors performed siRNA
mediated silencing and luciferase reporter assay which led
to the conclusion that PEA3 was responsible for increasing
the expression ofmiR-200bwhile ELK-1 was decreasingmiR-
200b expression by acting on its promoter.
3.6. miR-200c. miR-200c is another member of the miR-200
family that promotes anoikis. As with other miR-200 family
members, miR-200c is also capable of restoring E-cadherin
expression by targeting its transcriptional repressors. How-
ever, a study using a cell line that did not regain expression
of E-cadherin showed that miR-200c was still inhibiting
invasion and migration, suggesting that other pathways are
involved which work independently of E-cadherin [44]. This
led to a study by Howe et al. (2011) which investigated novel
genes that are targeted by miR-200c. Microarray analysis and
luciferase assay enabled them to identify a set of genes respon-
sible for conferring mesenchymal and neuronal properties
targeted by miR-200c [45]. Of these targets, TrkB was found
to be responsible for conferring anoikis resistance in breast
cancer cell lines. A receptor tyrosine kinase commonly found
in neurons, TrkB is also being discovered in cancer cells
owing to mutations or chromosomal rearrangements [64].
The role played by TrkB in cancer cells has also been studied,
where TrkB was found to activate the PI3K/Akt pathway to
enable survival in suspension [65]. In their studies, Howe
and colleague found that both overexpression of miR-200c
and downregulation of TrkB resulted in reversal of anoikis
resistance [45].
Although this study shows miR-200c to be a tumor
suppressor miRNA, further studies are required to under-
stand the regulatory mechanisms across cancer types. This is
because contrasting results were discovered in NSCLC, in a
study which reported that elevated serum level of miR-200c
correlated with shorter overall survival among patients [46].
3.7. miR-424-5p. Through microarray profiling performed
on anoikis resistant variant of the HCC cell line, miR-424-
5p was found to be significantly downregulated [47]. This
study by Zhang and colleagues further emphasized the role
played by E-cadherin on anoikis regulation. This is because
ICAT/CTNNBIP1, a 𝛽-catenin inhibitor, was found to be a
direct target of miR-424-5p. As a result, miR-424-5p is able
to maintain the level of E-cadherin/𝛽-catenin complex to
prevent EMT from occurring. In fact, they were also able
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to demonstrate a reversal of EMT in the HCC cell line
by increasing the expression of miR-424-5p. The role of 𝛽-
catenin in anoikis is also attributable to the activation of the
Wnt pathway, in which 𝛽-catenin interacts with transcrip-
tion factor lymphoid enhancer-binding factor 1 (LEF-1) to
regulate gene expression and subsequently inhibit anoikis
[66–68]. Furthermore, the study was advanced to clinical
investigation, allowing them to draw a correlation between
decreased expression of miR-424-5p with late clinical stage
in liver cancer progression. Together, the results from this
study highlight the therapeutic potential of miR-424-5p in
suppressing the malignant phenotype of metastatic liver
cancer.
3.8. miR-494. MiR-494 was chosen by Li and colleagues for
a study in pancreatic ductal adenocarcinoma (PDAC) as it
was found to target FOXM1 [48]. FOXM1 is a transcriptional
factor known to interact with 𝛽-catenin and enable its
translocation in glioma cells [69]. As 𝛽-catenin is a part of
the Wnt signaling pathway, its nuclear translocation aided by
FOXM1 will result in activation of various tumor promoting
genes. As such, by targeting FOXM1, miR-494 was found
to inhibit transcriptional activity of 𝛽-catenin and interrupt
the Wnt pathway [48]. Overexpression of miR-494 in PDAC
also suppressed anoikis resistance as was evident through the
colony formation assay.
The authors also investigated the reason for downregu-
lation of miR-494 in PDAC and found that loss of Smad4
expression in PDAC resulted in a defect in the TGF-𝛽 sig-
naling, which ultimately caused a downregulated expression
of miR-494. Overall, reduced expression of miR-494 serves
as an evidence for a defective TGF-𝛽 signaling pathway and
will be useful to determine themalignant nature of pancreatic
cancer.
4. MiRNAs Promoting Anoikis Resistance
Unsurprisingly, miRNAs that inhibit anoikis and confer
resistance have been found to be upregulated in cancer cells.
These miRNAs play oncogenic role by enabling survival of
cancer cells in suspension, thus enabling metastasis to occur.
The targets and pathways regulated by these miRNAs have
been analyzed and published (Table 1(b)).
4.1. miR-125b. Based on studies by Yu and colleagues using
mesenchymal stem cells, miR-125b was shown to protect cells
from anoikis induced cell death [49]. This study was done by
subjecting mesenchymal stem cells to growth in suspension
and screening for miRNA expression level. Mir-125b, which
was expressed in high level in suspended variant of the
humanmesenchymal stem cells (hMSC), was found to enable
survival for up to 7 days in suspension. The mechanisms by
which miR-125b conferred anoikis resistance which involve
ERK signaling were also demonstrated by the author.
By targeting and suppressing p53, miRNA-125b was able
to increase ERK phosphorylation in the mesenchymal stem
cells [70]. This study highlights another major component
involved in anoikis, p53, a tumor suppressor which is repeat-
edly shown to promote sensitivity to anoikis [15] and loss of
its expression is often correlated to anoikis resistance [71, 72].
The authors performed knockdown of miR-125b to study
its effect, which increased rate of anoikis in hMSC in suspen-
sion. However, whether or not miR-125b has similar effect on
cancer cells is yet to be determined, as further studies showed
that miR-125b did not protect human umbilical endothelial
cells (HUVEC) from anoikis, suggesting that this regulation
of anoikis may vary greatly across cell types [49].
4.2. miR-181a. A study by Wang et al. (2011) looked at an
interesting feature in breast cancer cell lines similar to stem
cells, which is to form spheres termed mammospheres when
in suspension. In their studies, upregulation of miR-181 by
TGF-𝛽 was found to be responsible for the regulation of
sphere formation [73]. However, how miR-181 was regulating
anoikis to enable sphere formation was not identified. This
was carried out in a recent study in breast cancer cells. Taylor
and colleagues looked at how miR-181a was contributing to
anoikis resistance and discovered that elevated level of miR-
181awas enabling higher survival rate for breast cancer cells in
suspension [50]. Transfection of miR-181a mimics in normal
murine mammary gland (NMuMG) cells and 4T1 breast
carcinoma rendered the cells less sensitive to anoikis.Western
blot and computational analysis showed Bim, a proapoptotic
protein, to be the anoikis related target formiR-181a.They also
made an interesting discovery when they found out that Bim
mRNA itself was not reduced by increasing level of miR-181a
expression, suggesting that the inhibition of BimmRNA takes
place at the translational level instead of the usual degradation
of mRNA. The authors also verified that the regulation of
Bim and anoikis takes place independently of the ERK/Akt
pathway, as miR-181a activity was not affected by inhibition
of Erk1/2 or Akt.
4.3. miR-145. In a recent study, Derouet and colleagues
investigated miR-145 when they found that its expression
was increased in esophageal adenocarcinoma (EAC) upon
chemoradiation treatment. Interestingly, overexpression of
miR-145 in EAC and esophageal squamous cell carcinoma
(ESCC) cell lines showed contrasting results, with miR-145
promoting anoikis resistance and cell growth in EAC while
producing the opposite results in ESCC [51].The authors also
performed cell adhesion assay and found that the expression
of miR-145 increased the cellular adhesion to fibronectin. In
this study, the target gene for miR-145 was not determined
or validated. However, since fibronectin is known to interact
with 𝛼5𝛽1 integrin to promote metastasis [74], the authors
suggest that the antianoikis effect in EAC could be due to
upregulation of 𝛼5𝛽1 integrin, based on results from the cell
adhesion assay.
4.4. miR-421. A study by Hao et al. (2011) comparing pan-
creatic cancer tissues with normal adjacent tissues showed
that miR-421 was overexpressed in the cancer tissues [52].
Developing on this result, they conducted another study to
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determine role of miR-421 in pancreatic cancer. Based on tar-
get prediction analysis and luciferase reporter assay, Smad4
was determined to be the target for miR-421. Predictably,
overexpression ofmiR-421 increased anoikis resistance, based
on the colony formation assay in which the overexpression
increased colony size and numbers in anchorage independent
condition. They also performed real-time PCR to investigate
the expression of transcriptional targets regulated by Smad4
and found that expression of p21 and p15, targets of TGF-
𝛽 and Id3 and Id4, and targets of bone morphogenetic
protein (BMP) were inhibited as expected, illustrating the
mechanism of how Smad4 targeting by miR-421 affects the
cancer cell phenotype.
4.5. miR-146a. Interestingly, miR-146a has shown diverse
expression pattern in different cancer cell types, such as being
upregulated in breast cancer [75] and cervical cancer [76]
while being downregulated in papillary thyroid carcinoma
[53]. MiR-146a has been previously found to target Smad4
in promyelocytic leukemia cell line in a study by Zhong et
al. (2010) [54]. In regard to anoikis regulation, Xiao and
colleagues investigated if miR-146a plays a similar role in
gastric cancer [55]. Based on luciferase reporter assay, they
were able to confirm the role miR-146a in suppressing Smad4
expression inmultiple gastric cancer cell lines [55].Theywent
on further to find the expression of miR-146a and Smad4
mRNA to be inversely correlated, supporting the luciferase
reporter assay result.
However, another study that analyzed gastric cancer
tissue samples found contrasting results, in which the expres-
sion of miR-146a was found to be downregulated in most
of the samples [56]. This discrepancy regarding contrasting
expression pattern of miR-146a needs to be addressed before
it can be applied in any therapeutic approach.
4.6. miR-483-3p. MiRNA-array differential analysis per-
formed by Hao and colleagues revealed miR-483-3p to
be upregulated in pancreatic cancer tissues. The authors
narrowed down target to be Smad4 and confirmed using
luciferase reporter assay [57]. Anoikis specific studies were
not performed, although overexpression studies showed
increased colony formation, which requires the cells to have
an increased resistance to anoikis.
Another study was done to determine the effects of
miR-483-3p by Bertero et al. (2011) in keratinocytes. This
study found the miRNA to regulate multiple genes related
to cell growth and overexpression of miR-483-3p in ker-
atinocytes restricted both migration and proliferation [58].
Taken together, these studies suggest a complex role played
by miR-483-3p that may help to suppress multiple oncogenic
aspects of cancer cells, making it a desirable candidate for
miRNA based therapy.
4.7. mir-199a. For this study, Zhang et al. (2012) employed
the approach of working backwards, by first selecting the
target gene as SMAD4 followed by a functional screening to
find candidate miRNAs that target this gene [59]. Using an
expression library of 388 human miRNAs, they performed
luciferase reporter assay to screen for miRNAs that target
Smad4 3󸀠UTR. This result combined the bioinformatics
analysis to narrow down the list to threemiRNAs that elicited
a significant reduction in Smad4 expression. One of these
miRNAs, miR-199a, was chosen for further studies. Based on
overexpression studies, they found that miR-199a promoted
anoikis resistance in gastric cancer cells by encouraging
anchorage independent growth.
Interestingly, another study that looked at TGF-𝛽1 signal-
ing pathway and miR-199a found the miRNA to be upregu-
lated in response to TGF-𝛽1 in human primary pulmonary
artery smooth muscle cells [77]. However, Zhang and col-
leagues were not able to replicate similar response in gastric
and liver cancer cell lines, SNU-16 and HEPG2, respectively,
suggesting that the regulation of TGF-𝛽1 pathway bymiRNAs
is still unclear and differs with cell lines [59].
5. MiRNAs and Signaling Pathways
Regulating Anoikis
Although anoikis is a complex regulatory mechanism span-
ning multiple signaling pathways and mechanisms [8], anal-
ysis of dysregulated miRNAs in cancer cells have revealed
several key pathways that work to either promote or inhibit
anoikis. While different genes are targeted by these miRNAs,
it is clear that the targets are often components of the same
pathways (Table 1), highlighting the important role played by
these pathways.
5.1. PI3K/AKT Pathway and miRNAs Promoting Anoikis. It
is evident from the miRNAs reviewed here (Table 1(a)) that
the PI3K/Akt pathway is the main target for majority of
miRNAs promoting anoikis sensitivity. PI3K/Akt pathway
is a prosurvival signaling pathway that plays a major role
in various cellular functions such as proliferation, invasion,
and angiogenesis. While it has been well established that the
PI3K/AKT pathway components are often mutated to enable
abnormal activation in various cancer types [78, 79], studies
on miRNAs now show that cancer cells also downregulate
miRNAs that targets this pathway as a strategy to evade
anoikis. When such miRNAs (Table 1(a)) are overexpressed,
PI3K/Akt pathway is disrupted and cancer cells exhibit
increased sensitivity towards anoikis. Since PI3K/Akt path-
way is well known to promote proliferation of various cancer
types, targeting this pathway has become a desirable approach
in cancer treatment, with extensive studies being done on this
pathway in cancer cells. As a result, several drugs targeting
components of this pathway are currently undergoing clinical
trials [80, 81].
5.2. TGF-𝛽/SMAD Pathway and miRNAs Inhibiting Anoikis.
A tumor suppressor, Smad4 protein acts as an effector
signaling molecule that works downstream of the TGF-𝛽
superfamily signaling [82]. Other components of the Smad
family are functionally split into two pathways, with Smad2
and Smad3 in the TGF-𝛽/activin pathway and Smad1, Smad5,
and Smad8 in the BMP pathway. When these Smad proteins
are phosphorylated by receptors, a heteromeric complex is
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formedwith Smad4 as a partner, enabling the translocation of
the complex to the nucleus for either direct interaction with
DNA or with other transcription factors [83, 84]. Overall, the
TGF-𝛽/Smad pathways govern a plethora of functionalities
including cell growth, survival, and differentiation [85].
A study done by Ramachandra and colleagues provided
a better understanding regarding one of the mechanisms
by which Smad4 regulates anoikis sensitivity in cancer cells
[86]. By overexpressing Smad4, 𝛽1 integrin expression was
found to be increased. This is consistent with another study
which demonstrated that𝛽1 integrin expression is augmented
by the TGF-𝛽 pathways [87]. In its unligated form, which
results from detachment from the ECM, 𝛽1 integrin actively
promotes anoikis through caspase-8 mediated cell death [12].
With an important role in maintaining anoikis, Smad4 is
often defective in cancer by means of mutation or deletion
[82]. However, increasing number of studies are now showing
that the TGF-𝛽/Smad pathway is also dysregulated by many
oncogenicmiRNAs as a way to inhibit anoikis and initiate the
metastatic cascade as presented in this review (Table 1(b)).
6. Current miRNA Based Therapeutics
MiRNA based cancer therapy has entered a very important
stage in development, with several miRNAs and miRNA
inhibitors being advanced past preclinical stages by pharma-
ceutical companies [88]. This development is instrumental
to the study of miRNA as it has the consequence of proving
that miRNAs’ therapeutic potential can be translated from
in vitro cancer model to clinical application in patients. An
example of such miRNA based drug is miRNA-122 inhibitor
that is capable of treating Hepatitis C infection. Interestingly,
two separate companies are working on different miR-122
inhibitors, with Santaris Pharma currently at Phase II stage
andRegulusTherapeutics at Phase I stage of clinical trial [89].
As for cancer therapy, one promisingmiRNA based drug,
MRX34, is currently in Phase I stage [89]. MRX34 is a
mimic of miR-34a, a well-known tumor suppressor miRNA
in various cancer types [90]. By adopting a similar approach,
anoikis related miRNAs can be great candidates for cancer
treatment. Since anoikis is an early barrier for cancer cells
to become metastatic, targeting anoikis related miRNAs will
enable the suppression of cancer cells from becoming more
aggressive. In addition, identifying individual miRNAs that
regulate multiple cancer cell phenotypes such as anoikis
resistance and metastasis will allow the development of a
more potent miRNA based drug.
However, the application of anoikis related miRNAs in
cancer therapy need not be restricted to treatment alone. As
shown by multiple studies, elevated serum level of oncogenic
miRNAs has been evident in cancer patients. Based on the
growing body of knowledge on miRNAs regulating anoikis,
a personalized approach to cancer therapy can be designed,
where patients exhibiting increased expression of miRNAs
inhibiting anoikis can be selected for a targeted treatment
using inhibitors of those miRNAs.
7. Conclusion
Anoikis regulation bymiRNA has proven to be a complicated
yet important topic, with an increasing number of miRNAs
found to play critical role in both promoting and inhibiting
anoikis. From the evaluation of miRNAs involved in mod-
ulating anoikis, it has become evident that anoikis promot-
ing miRNAs make for attractive candidates for anticancer
therapy, as it has shown to be capable of not only curbing
metastasis before it happens, but also reversing themalignant
phenotype of an aggressive cancer. Furthermore, it is also
apparent how some of the same signaling pathways have been
repeatedly shown to be targets for various anoikis related
miRNAs, such as the TGF-𝛽/Smad and PI3K/Akt pathways,
thus emphasizing the need to focus on these pathways in
engineering cancer treatments.
While miRNAs promoting anoikis can be useful in
therapeutic approach, miRNAs inhibiting anoikis can also
play useful role through a novel prognosis method in cancer
detection, as elevated levels of miRNAs conferring anoikis
resistance have been detected in serum, showing high
correlation with survival rate of patients. However, before
miRNAs can be developed into viable anticancer treatment,
themultiple functions played bymiRNAs and the contrasting
roles across different cell types need to be addressed.
In addition, another key issue that requires attention is
the challenge of delivering known tumor suppressormiRNAs
to cancer cells. If these issues are addressed accordingly,
miRNAs regulating anoikis will greatly contribute to effective
cancer prognosis and potential development of anticancer
drugs.
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